Friday, October 13, 2017 -- High cholesterol levels have been associated with breast cancer spreading to other sites in the body, but doctors and researchers don't know the cause for the link.
Wednesday, October 11, 2017 -- (Reuters) - Merck & Co Inc said on Wednesday it will not seek regulatory approval for its experimental cholesterol drug, anacetrapib, as the clinical profile of the treatment does not support regulatory filings.
Wednesday, October 11, 2017 -- A study determines if a treatment lowering LDL-cholesterol in patients at high risk for adverse cardiovascular events further reduces the risk of adverse outcomes such as heart attack or stroke. It is estimated that roughly 30 million people worldwide take statins to lower LDL-cholesterol levels. The buildup of LDL-cholesterol, dubbed bad cholesterol, in the arteries […] The post Does Reducing LDL-Cholesterol Reduce the Risk of Adverse Outcomes? appeared first on Medical News Bulletin.
Thursday, October 12, 2017 -- Merck & Co has said it will not file its cholesterol drug anacetrapib with regulators, saying that trial results are not good enough for clinical filings. The news came in a brief statement, which followed a surprise success for anacetrapib in...
Monday, October 16, 2017 -- (MedPage Today) -- So why do doctors still rely on LDL?
Thursday, October 12, 2017 -- Merck has decided to abandon efforts to market a closely watched experimental cholesterol medicine after mediocre test results.
Monday, October 16, 2017 -- AbstractBackground Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds low-density lipoprotein receptor (LDLR), preventing its recycling. PCSK9 is a risk predictor and a biotarget in atherosclerosis progression. Objectives The aim of this study was to determine whether the PCSK9-LDLR axis could predict risk in patients with heart failure (HF). Methods The BIOSTAT-CHF (Biology Study to Tailored Treatment in Chronic Heart Failure) is a multicenter, multinational, prospective, observational study that included patients with worsening HF signs and/or symptoms. The primary endpoints were all-cause mortality and the composite of mortality or unscheduled hospitalizations for HF. We implemented Cox proportional hazard regression to determine the simultaneously adjusted effect of PCSK9 and LDLR on both outcomes when added to the previously validated BIOSTAT-CHF risk
Monday, October 16, 2017 -- Abstract Diabetes, hyperlipidemia, and hypertension are modifiable risk factors that predict cardiovascular disease events. The effect of these risk factors on incident cardiovascular disease increases with progressively higher levels of glucose, low-density lipoprotein cholesterol, and blood pressure. The thresholds for initiating treatment of these modifiable risk factors and the optimal goals of risk factor modification are a focus of primary prevention research. Although an aggressive approach is appealing, adverse events may occur, and potential physiological barriers may exist. This paper discusses primary prevention of coronary heart disease that may be achieved through modification of diabetes, hyperlipidemia, and hypertension by summarizing current guidelines and pertinent clinical trial data from intervention trials that included a primary prevention cohort.
Sunday, October 15, 2017 -- If you have diabetes, then you may have been told to steer clear of many common types of noodles and pasta, as they can cause spikes and drops in your blood sugar levels. Well, thanks to Singapore researchers, you … The post Could noodles help lower your cholesterol? appeared first on Bel Marra Health - Breaking Health News and Health Information.